ArticleCureus2025
Long-Term Peritoneal Dialysis in Hereditary Transthyretin Amyloidosis: A Case Report and Management Challenges.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloidosis is a disease characterized by extracellular deposition of misfolded proteins, causing progressive organ damage, including end-stage kidney disease (ESKD). Patients with ESKD due to amyloidosis face poor survival rates, and evidence to guide optimal management strategies is lacking. We present the case of a 64-year-old woman with hereditary transthyretin (TTR) amyloidosis and ESKD who has been successfully treated with peritoneal dialysis (PD) for over 33 months. This report highlights the challenges encountered during follow-up, including the progression of peripheral neuropathy, and underscores the need for further investigation leading to targeted therapies to prevent disease progression and complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.